New study pits JAK inhibitors against standard therapy for rare lung disease
NCT ID NCT07406932
First seen Feb 15, 2026 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study will compare two types of drugs—JAK inhibitors and calcineurin inhibitors—as first treatments for lung scarring (interstitial lung disease) caused by antisynthetase syndrome, a rare autoimmune condition. About 80 adults aged 18 to 75 with active lung disease who have not yet taken immunosuppressants will be enrolled. The goal is to see which drug better preserves lung function and improves survival over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.